oxxa, I think you're forgetting that they need us more than we need them.
Without us Car-Ts can only treat blood cancers, with us they increase their client base by 900%.
There are also plenty of Car-T cells around, anyone who misses a deal with IMU will be left with only blood cancers.
I don't think we will be begging for deals or taking whatever is offered.
I'm not buying into the price argument, but I feel sure $2 ($12B company valuation) will be on the low side for a Pharma that treats all cancers.
Add to My Watchlist
What is My Watchlist?
